Literature DB >> 4083860

Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.

J R Perfect, D T Durack.   

Abstract

Amphotericin B and N-D-ornithyl amphotericin B methyl ester were compared for therapeutic efficacies against experimentally induced cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis in rabbits. Antifungal activity of the two polyenes in vitro was similar for the yeasts used in these experiments. N-D-ornithyl amphotericin B methyl ester gave a slightly higher concentration in serum than amphotericin B did, but both drugs had similar elimination curves, and penetration into the cerebrospinal fluid was poor for both. Despite these similarities between the two polyenes, amphotericin B was much more effective than N-D-ornithyl amphotericin B methyl ester in the treatment of cryptococcal meningitis in rabbits. For C. albicans endocarditis, both polyenes had similar cure rates, but in vitro measurement of fungicidal activity in serum did not predict treatment outcome. For C. albicans pyelonephritis, both polyenes showed efficacy; because higher doses of the less toxic methyl ester could be used, it sterilized the urinary tract more often than amphotericin B. These studies indicate that in vivo and in vitro experiments may be needed to predict the results of treatment with polyenes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4083860      PMCID: PMC180322          DOI: 10.1128/AAC.28.6.751

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Comparative in vitro antifungal activity of amphotericin B and amphotericin B methyl ester.

Authors:  W R Howarth; R P Tewari; M Solotorovsky
Journal:  Antimicrob Agents Chemother       Date:  1975-01       Impact factor: 5.191

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  A pharmacologic guide to the clinical use of amphotericin B.

Authors:  D D Bindschadler; J E Bennett
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

4.  In vitro and in vivo comparisons of amphotericin B and N-D-ornithyl amphotericin B methyl ester.

Authors:  G S Kobayashi; J R Little; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

5.  Comparative chemotherapeutic activity of amphotericin B and amphotericine B methy ester.

Authors:  D P Bonner; R P Tewari; M Solotorovsky; W Mechlinski; C P Schaffner
Journal:  Antimicrob Agents Chemother       Date:  1975-06       Impact factor: 5.191

6.  Comparison of amphotericin B and amphotericin B methyl ester: efficacy in murine coccidioidomycosis and toxicity.

Authors:  R M Lawrence; P D Hoeprich
Journal:  J Infect Dis       Date:  1976-02       Impact factor: 5.226

7.  Experimental Candida albicans endocarditis: characterization of the disease and response to therapy.

Authors:  M A Sande; C R Bowman; R A Calderone
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

8.  Amphotericin B and amphotericin B methyl ester ascorbate. I. Chemotherapeutic activity against Candida albicans, Cryptococcus neoformans, and Blastomyces dermatitidis in mice.

Authors:  H H Gadebusch; F Pansy; C Klepner; R Schwind
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

9.  Comparative toxicological studies of amphotericin B methyl ester and amphotericin B in mice, rats, and dogs.

Authors:  G R Keim; P L Sibley; Y H Yoon; J S Kulesza; I H Zaidi; M M Miller; J W Poutsiaka
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

10.  Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis.

Authors:  E Lefler; E Brummer; A M Perlman; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

View more
  18 in total

1.  Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.

Authors:  J R Perfect; K A Wright; M M Hobbs; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

3.  Comparative in vitro and in vivo evaluation of N-D-ornithyl amphotericin B methyl ester, amphotericin B methyl ester, and amphotericin B.

Authors:  R M Parmegiani; D Loebenberg; B Antonacci; T Yarosh-Tomaine; R Scupp; J J Wright; P J Chiu; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

4.  Effect of nystatin, amphotericin B and amphotericin B methyl ester on Saccharomyces cerevisiae with different lipid composition.

Authors:  M A de Resende; F Alterthum
Journal:  Mycopathologia       Date:  1990-12       Impact factor: 2.574

5.  Treatment of experimental disseminated candidiasis with cilofungin.

Authors:  J R Perfect; M M Hobbs; K A Wright; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.

Authors:  J R Perfect; D L Toffaletti; T H Rude
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans.

Authors:  J K Lodge; E Jackson-Machelski; D L Toffaletti; J R Perfect; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

8.  In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

Authors:  J R Perfect; G M Cox; R K Dodge; W A Schell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome.

Authors:  M Radetsky; R C Wheeler; M H Roe; J K Todd
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

10.  An alternative animal model for comparison of treatments for cryptococcal meningitis.

Authors:  L K Najvar; R Bocanegra; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.